Analyst Interview: Cynapsus Therapeutics Still A Top Pick
- The following is a transcript of an interview with Zacks Sr. Biotech analyst Jason Napodano.
- The recent financing pulled in $23+ million in cash and looks to be enough to fund operations and development of APL-130277 though the NDA filing.
- Jason continues to believe Cynapsus shares represent a compelling value for investors.
- Target price is $2.15 per share, or 250% upside from today.